{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 37,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_takeaways",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The slide uses a table to compare clinical outcomes across patient subgroups (all, resistant, refractory) and a callout box for key takeaways.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/11",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Key Clinical Takeaways: Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5f9b03e-fd9a-4432-8e61-87e86590614e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.36,
        "y": 0.7
      },
      "kind": "disclaimer",
      "text": "Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Olvi-Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87085abb-f5b0-4812-963c-779ee151fd85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.36,
        "y": 0.21
      },
      "kind": "table",
      "text": "Overall Response Rate (ORR) & Progression-Free Survival (PFS) table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c52c835-bafd-4f27-9fb9-fa62fbb12eb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c02b7e7f-1908-4d82-bafd-11e4fed5083b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "d8cf164b-9dc3-46c5-a3b8-38b3a4156c20",
      "evidence": "table/data: Overall Response Rate (ORR) & Progression-Free Survival (PFS) table",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "c8855738-8855-419f-9061-e7412c0d080f",
      "evidence": "Key takeaways are presented as a bulleted list.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "83a3aa16-5d5b-40f0-bd18-2beeecaa8bff",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction section highlights the results of phase 1b trials and the potential of Olvi-Vec.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "74f1324f-3d80-4446-a16d-591787824d08",
      "evidence": "The loop opens by presenting the challenges of current treatments and closes by showing the benefits of Olvi-Vec.",
      "position": 0,
      "objective": "Highlight the cost of not using Olvi-Vec",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}